



Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application:

--1. (currently amended) A compound of formula 1



wherein:



or an acid addition salt thereof.--

--2. (cancelled)--

--3. (cancelled)--

--4. (cancelled)--

--5. (cancelled)--

--6. (cancelled)--

--7. (currently amended) ~~A~~The compound of formula 1 according to ~~one of~~ claims 1 to 6, wherein the hydroxy group in the group R^1 is in the *ortho* or *meta* position to the amino group.--

--8. (previously presented) 1-[3-(4-methoxybenzylamino)-4-hydroxyphenyl]-2-[4-(1-benzimidazolyl)-2-methyl-2-butylamino]ethanol, or an acid addition salt thereof.--

--9. (cancelled)--

--10. (cancelled)--

--11. (currently amended) The compound according to one of claims 1, ~~2, 3, 57~~, or 8, 9, ~~or 10~~, wherein the acid addition salt thereof is formed with a pharmacologically acceptable acid.--

--12. (currently amended) A method of treating bronchial asthma, the inflammatory component in COPD, premature onset of labor in midwifery (tocolysis), atrio-ventricular block, bradycardiac hearth rhythm disorders, circulatory shock, or itching and inflammation of the skin in a host in need of such treatment, the method comprising administering to the host the compound according to one of claims 1, ~~2, 3, 57~~, or 8, 9, ~~or 10~~.--

--13. (currently amended) A pharmaceutical composition comprising a compound according to one of claims 1, ~~2, 3, 57~~, or 8, 9, ~~or 10~~ and a conventional excipient or carrier.--

--14. (original) The pharmaceutical preparation according to claim 13, further comprising at least one other active substance selected from the group consisting of anticholinergics, betamimetics, antiallergics, PAF antagonists, leukotriene antagonists, and steroids.--

--15. (original) The pharmaceutical preparation according to claim 14, further comprising tiotropium bromide.--

--16. (cancelled)--

--17. (cancelled)--